Latest Stocks: LeMaitre Vascular Inc (LMAT) Shares Bought by Russell Investments Group Ltd.

Latest Stocks: LeMaitre Vascular Inc (LMAT) Shares Bought by Russell Investments Group Ltd.

Russell Investments Group Ltd. boosted its position in shares of LeMaitre Vascular Inc (NASDAQ:LMAT) by 211.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 150,413 shares of the medical instruments supplier’s stock after buying an additional 102,078 shares during the period. Russell Investments Group Ltd.’s holdings in LeMaitre Vascular were worth $3,705,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Numeric Investors LLC purchased a new position in shares of LeMaitre Vascular during the fourth quarter worth approximately $707,000. Arrowstreet Capital Limited Partnership purchased a new position in shares of LeMaitre Vascular during the fourth quarter worth approximately $238,000. AQR Capital Management LLC raised its position in shares of LeMaitre Vascular by 41.6% in the fourth quarter. AQR Capital Management LLC now owns 162,363 shares of the medical instruments supplier’s stock worth $4,114,000 after buying an additional 47,664 shares in the last quarter. Bogle Investment Management L P DE raised its position in shares of LeMaitre Vascular by 37.3% in the fourth quarter. Bogle Investment Management L P DE now owns 100,481 shares of the medical instruments supplier’s stock worth $2,546,000 after buying an additional 27,316 shares in the last quarter. Finally, A.R.T. Advisors LLC purchased a new position in shares of LeMaitre Vascular during the fourth quarter worth approximately $266,000. 61.80% of the stock is currently owned by hedge funds and other institutional investors.

Shares of LeMaitre Vascular Inc (NASDAQ:LMAT) opened at 31.30 on Tuesday. The firm has a market capitalization of $588.72 million, a price-to-earnings ratio of 52.25 and a beta of 0.63. LeMaitre Vascular Inc has a 12-month low of $13.52 and a 12-month high of $33.22. The stock’s 50 day moving average price is $29.52 and its 200 day moving average price is $25.20.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Thursday, May 4th. The medical instruments supplier reported $0.16 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.13 by $0.03. LeMaitre Vascular had a return on equity of 12.83% and a net margin of 12.19%. The business had revenue of $24.10 million during the quarter, compared to analysts’ expectations of $23.48 million. The firm’s revenue was up 18.7% on a year-over-year basis. Equities research analysts expect that LeMaitre Vascular Inc will post $0.70 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 8th. Investors of record on Wednesday, May 24th will be given a dividend of $0.055 per share. This represents a $0.22 annualized dividend and a yield of 0.70%. The ex-dividend date is Monday, May 22nd. LeMaitre Vascular’s payout ratio is 32.73%. Several analysts have recently issued reports on LMAT shares. Stifel Nicolaus increased their target price on LeMaitre Vascular from $25.00 to $29.00 and gave the stock a “buy” rating in a report on Friday, April 28th. Canaccord Genuity reissued a “buy” rating and set a $28.00 target price on shares of LeMaitre Vascular in a report on Thursday, April 27th. Zacks Investment Research raised LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $36.00 target price on the stock in a report on Friday, April 28th. Barrington Research lowered LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 22nd. Finally, First Analysis started coverage on LeMaitre Vascular in a report on Tuesday, March 21st. They set an “overweight” rating and a $29.00 target price on the stock. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $26.43.

In related news, Chairman George W. Lemaitre sold 87,342 shares of the business’s stock in a transaction dated Wednesday, May 3rd. The stock was sold at an average price of $32.35, for a total transaction of $2,825,513.70. Following the completion of the transaction, the chairman now directly owns 3,484,149 shares in the company, valued at $112,712,220.15. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider David B. Roberts sold 5,900 shares of the business’s stock in a transaction dated Friday, March 10th. The stock was sold at an average price of $22.44, for a total value of $132,396.00. Following the transaction, the insider now owns 46,945 shares of the company’s stock, valued at $1,053,445.80. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 323,705 shares of company stock valued at $10,042,728. 28.90% of the stock is owned by company insiders. About LeMaitre Vascular

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular Inc (NASDAQ:LMAT). Receive News & Ratings for LeMaitre Vascular Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for LeMaitre Vascular Inc and related companies with MarketBeat.com’s FREE daily email newsletter.

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular Inc (NASDAQ:LMAT).

Related posts

Leave a Comment